November 2026

The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.

A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers

Primary end point results from the phase 2 GEM-TECTAL trial, presented at IMS 2026 in Glasgow, Scotland, support further study of a transplant-free, bispecific-based frontline strategy for patients with the hardest-to-treat disease.

Oncologists reveal why breakthrough cancer drugs still stall—referral gaps, payer delays, caregiver needs, and pharmacy bottlenecks reshape access across tumor types.

Five-year results from cohort A of CARTITUDE-2, presented at the International Myeloma Society Annual Meeting, show long, treatment-free remissions in lenalidomide-refractory patients who had 1 to 3 prior lines of therapy.

At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.

A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.

At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Biomarker testing, treatment sequencing, drug delivery, and rural access barriers were examined during an IVBM event in Salt Lake City.

At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.

For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.

More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Clinicians from University of Chicago Medicine, Northwestern Medicine, and Loyola Medicine said bispecific antibodies for early-relapse myeloma can be given safely outside the hospital, but staffing, after-hours triage, and community confidence have yet to catch up.

Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.

MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.

The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.

The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence agents, with outside records retrieval to follow.

Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.